Taming autoimmunity: Alpha-1 antitrypsin overexpressing mesenchymal stromal cells promote regulatory T cell crosstalk to reverse diabetes
Molecular Therapy · 2026-07 · 34 (7) · 4181-4199
DOI: 10.1016/j.ymthe.2026.03.032 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy, 2026-07. Verfasst von Hua Wei und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Medical University of South Carolina, Charleston, SC, USA. Hauptthemen laut MEDLINE: T-Lymphocytes, Regulatory, alpha 1-Antitrypsin, Mesenchymal Stem Cells, Autoimmunity. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NCI NIH HHS, NIGMS NIH HHS.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Mesenchymal stem/stromal cell (MSC) therapy holds promise as a therapeutic option in diabetes treatment. Anti-inflammatory and immunomodulatory activities are enhanced when MSCs are engineered to overexpress alpha-1 antitrypsin (AAT-MSCs). Because a single infusion of AAT-MSCs reversed new-onset diabetes in over 50% of the female non-obese diabetic mice, we used single-cell RNA sequencing, flow cytometry, and functional analyses to characterize how AAT-MSCs modulate CD4+ and CD8+ T cells in pancreatic lymph nodes (PLNs) and islets. AAT-MSC treatment increased T regulatory cells (Tregs) and more effectively suppressed T cell proliferation when stimulated with anti-CD3/CD28 antibodies. Treated mice exhibited reduced T helper 1 cells and CD8+ cytotoxic T cells. In vitro studies confirmed the capacity of AAT-MSCs to promote Treg expansion in both mouse and human cells, drive CD8+ T cells toward an exhausted phenotype, and enhance mouse and human islet cell survival. CellChat analysis showed that AAT-MSC therapy strengthens intercellular communication, especially signals originating from Tregs toward other PLN and islet cell populations. These findings clarify how AAT-MSCs modulate immune response and support their potential clinical application for type 1 diabetes and other autoimmune or inflammatory conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Medical University of South Carolina, Charleston, SC, USA.
- Department of Neuroscience, Medical University of South Carolina, Charleston, SC, USA.
- Department of Medicine, Medical University of South Carolina, Charleston, SC, USA.
- Department of Surgery, Medical University of South Carolina, Charleston, SC, USA; Ralph H. Johnson Veterans Affairs Medical Center, Charleston, SC, USA. Electronic address: wangho@musc.edu.
Förderung
- NIDDK NIH HHS
- NCI NIH HHS
- NIGMS NIH HHS
- BLRD VA
- CSRD VA
- Department of Veterans Affairs
- Medical University of South Carolina
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Wei, H., Gou, W., Kim, J., Subramanian, S., Yeung, T., Chakraborty, P., Lotfy, A., Mehrotra, S., Berto, S., Strange, C., & Wang, H. (2026). Taming autoimmunity: Alpha-1 antitrypsin overexpressing mesenchymal stromal cells promote regulatory T cell crosstalk to reverse diabetes. Molecular Therapy, 34(7), 4181-4199. https://doi.org/10.1016/j.ymthe.2026.03.032
Vancouver
Wei H, Gou W, Kim J, Subramanian S, Yeung T, Chakraborty P, et al. Taming autoimmunity: Alpha-1 antitrypsin overexpressing mesenchymal stromal cells promote regulatory T cell crosstalk to reverse diabetes. Molecular Therapy. 2026;34(7):4181-4199. doi:10.1016/j.ymthe.2026.03.032
BibTeX
@article{Wei2026,
author = {Wei, Hua and Gou, Wenyu and Kim, Judong and Subramanian, Suganya and Yeung, Tiffany and Chakraborty, Paramita and Lotfy, Ahmed and Mehrotra, Shikhar and Berto, Stefano and Strange, Charlie and Wang, Hongjun},
title = {Taming autoimmunity: Alpha-1 antitrypsin overexpressing mesenchymal stromal cells promote regulatory T cell crosstalk to reverse diabetes},
journal = {Molecular Therapy},
year = {2026},
volume = {34},
number = {7},
pages = {4181--4199},
doi = {10.1016/j.ymthe.2026.03.032}
}
EUVIMED